Circular RNA profile of infantile hemangioma by microarray analysis

Cong Fu, Renrong Lv, Guangqi Xu, Linfeng Zhang, Jianhai Bi, Li Lin, Xiaowen Liu, Ran Huo*

Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China

* huoran@medmail.com.cn

Abstract

Background

Circular RNAs (circRNAs) are a recently identified class of noncoding RNAs that participate in several physiological processes. However, the expression of circRNAs in infantile hemangioma (IH) remains unknown.

Methods

The profile of circRNAs was assessed by microarray in four pairs of IH and adjacent skin tissues. The expression of circRNAs was validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, circRNA-microRNAs (miRNA)-mRNA networks were constructed using bioinformatics tools.

Results

234 up- and 374 down-regulated circRNAs were identified in IH by microarray. Among them, the expression of two up-regulated circRNAs (hsa_circRNA_100933 and hsa_circRNA_100709) and one down-regulated circRNA (hsa_circRNA_104310) was confirmed by qRT-PCR. In addition, 3,019 miRNA response elements (MREs) of circRNAs were predicted, and two circRNA-miRNA-mRNA networks were constructed, including 100 and 94 target genes of hsa_circRNA_100933 and hsa_circRNA_104310, respectively. GO and pathway analysis showed that both networks participated in angiogenesis and vascular development-related biological processes.

Conclusions

This is the first study to reveal the profiling of circRNAs in IH and pave the way for further characterization of the role of circRNAs in the pathogenesis of IH.
Introduction

Infantile hemangioma (IH) is a common vascular tumor in infancy, especially in females and premature with an increasing incidence of 3–10%[1]. Most IHs possess a unique life cycle composed of proliferation and involution stage; the proliferation is usually rapidly in the first year, followed by spontaneous resolution until 3–7 year old [2]. Notably, the rapid growth during proliferation stage may lead to ulceration, scarring, disfiguring, or even life-threatening complications [3].

Angiogenesis and vasculogenesis have been recognized as underlying neovascularization in IH [4,5]. The histopathological feature of proliferative IH includes masses of endothelial cells and closely packed capillaries. A high level of circulating endothelial progenitor cells (EPCs) support the hypothesis that IHs originate from intrinsic EPC [6,7]. Moreover, the theory of placenta origin suggests that the impairment of placenta during gestation may contribute to endothelial embolization and proliferation [8]. Accumulating evidence suggests that the pla-centa antigen glucose transporter 1 (GLUT 1) expresses in endothelial cells of IH and is an immunochemical marker for IH [9]. The extrinsic factors, such as hypoxia and acidosis and intrinsic factors, such as hypoxia-inducible factor 1 alpha (HIF1-α), vascular endothelial growth factors (VEGFs), and other angiogenic factors have been suggested to contribute to the development of IH [10,11]. Despite multiple hypotheses, the pathogenesis of IH is largely unknown.

Based on RNA sequencing data, a majority of human transcripts are non-coding RNAs (ncRNAs), with < 2% of the genome encoding the proteins [12]. An increasing volume of evidence suggests that ncRNAs are vital regulators in the vascular development of various disorders. Our previous study comparing the profile of long noncoding RNAs (IncRNAs) in IH and adjacent normal tissues revealed that IncRNAs are involved in angiogenesis and vascular biology [13]. Moreover, microRNAs (miRNAs), known as the common group of small ncRNAs, have been proved to play a pivotal role in IH pathogenesis. A recent study showed that chromosome 19 miRNA cluster (C19MC) was overexpressed in both IH tissues and blood samples, identifying C19MC as a candidate biomarker of IH [14]. MiR-382 is overexpressed in IH endothelial cells and contributes to IH development [15]. The inhibition of miR-130a suppresses the cell growth and angiogenesis of IH [16]. Nonetheless, the mechanism underlying the regulation of miRNA in IH necessitates further studies.

Circular RNAs (circRNAs) are a recently identified class of ncRNAs that participate in several physiological processes[17]. Although circRNAs were discovered in 1972, they were mistaken for derivatives of mis-splicing [18,19]. The biology and function of circRNAs have aroused attention until 2012 thanks to high throughput technology[20]. Importantly, circRNAs have been demonstrated to serve as miRNA sponges for regulating gene expression [21,22]. Some circRNAs compete with mRNAs for the same miRNA binding sites to form an integral network of posttranscriptional regulation, termed as the competing endogenous RNAs (ceRNAs) network [23,24]. Recently, circRNAs profiling have been identified in several kinds of disorders, especially in tumors, such as cutaneous squamous cell carcinoma[25], epithelial ovarian carcinoma[26], basal cell carcinoma[27]. However, the circRNAs involved in IH are yet to be explored. Interestingly, a recent study identified a circRNA profile in human umbilical endothelial cells under hypoxic or normoxic conditions and indicated that circRNA cZNF292 was up-regulated by hypoxia and controlled the formation of tubers and spheroid sprouting of endothelial cells [28]. These characteristics indicate that circRNAs might play an important role in the etiology of IH.

Therefore, in this study we identified the profile of circRNAs in four pairs of proliferative IH and adjacent skin tissues by high-throughput microarray. Subsequently, a total of 8
circRNAs were examined using quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 10 paired IH and adjacent skin tissues. The most significant up- (hsa_circRNA_100933) and down-regulated (hsa_circRNA_104310) circRNA were chosen for further study. Next, we predicted the interaction between circRNAs and miRNAs and constructed hsa_circRNA_100933-miRNA-mRNA and hsa_circRNA_104310-miRNA-mRNA networks using the bioinformatics approach.

Methods

Ethics statement

This study was approved by the Institutional Ethics Review Board of Shandong Provincial Hospital Affiliated to Shandong University (No. 2016–206). Written informed consents were obtained from the guardians on behalf of the children enrolled in this study.

Patients and samples

The proliferative IH was diagnosed by two independent doctors according to clinical and pathological features. IH samples (Table 1) were excised at the Department of Plastic Surgery of Shandong Provincial Hospital between June 2016 and February 2017. Four pairs of samples were used for microarray. Then, total 10 pairs were used for further validation. The excised samples were immersed overnight in RNAlater (Qiagen, Hilden, Germany) at 4°C and preserved at -80°C.

RNA isolation and quality control

RNA from each sample was isolated by TRIzol reagent (Invitrogen life technologies, Carlsbad, USA) based on the manufacturer’s instructions. The purity and concentrations of total RNA samples were determined with NanoDrop ND-1000. RNA integrity was tested by denaturing agarose gel electrophoresis.

Microarray and data analysis

The complete microarray data were deposited in Gene Expression Omnibus (GEO) database (accession number GSE93522 [NCBI tracking system #18429863]). Sample labeling and array hybridization were performed based on the Arraystar’s protocol. Total RNA from each sample was treated with RNase R (Epicenter, Madison, USA) to enrich circular RNAs and remove linear RNAs. Subsequently, fluorescent cRNA were obtained by amplification and transcription

Table 1. Clinicopathological characteristics of IH patients.

| Subject | Gender | Age       | Localization      | Previous therapy | Immunochemistry |
|---------|--------|-----------|-------------------|------------------|-----------------|
| 1       | Female | 5 months  | Thoracic wall     | None             | GLUT+           |
| 2       | Female | 4 months  | Back              | None             | GLUT+           |
| 3       | Male   | 4 months  | Back              | None             | GLUT+           |
| 4       | Female | 7 months  | Back              | None             | GLUT+           |
| 5       | Female | 6 months  | Lumber region     | None             | GLUT+           |
| 6       | Female | 4 months  | Back              | None             | GLUT+           |
| 7       | Male   | 6 months  | Scalp             | None             | GLUT+           |
| 8       | Female | 3 months  | Thoracic wall     | None             | GLUT+           |
| 9       | Female | 9 months  | Back              | None             | GLUT+           |
| 10      | Male   | 2 months  | Back              | None             | GLUT+           |

https://doi.org/10.1371/journal.pone.0187581.t001
of circular RNAs through random priming (Arraystar Super RNA Labeling Kit). The labeled cRNAs (pmol Cy3/μg cRNA) were purified by RNeasy Mini Kit (Qiagen) and assessed with NanoDrop ND-1000. Then blocking agent (10×5μL) and fragmentation buffer (25×1μL) were added to make each labeled cRNA fragmented, followed by heating at 60˚C for 30 min. Labeled cRNA was diluted with hybridization buffer (2×25μL). Hybridization solution (50 μL) was added into the gasket slide. Finally, microarray slide was incubated for 17 h at 65˚C in an Agilent Hybridization Oven. The hybridized arrays were washed, fixed, and scanned using the Agilent Scanner G2505C.

R software limma package was used for data normalization and calculation. The fold-change between the IH and adjacent skin tissues was calculated. The statistical significance was calculated by t-test. circRNAs with fold-change ≥2 and P-values ≤0.05 were regarded as a significant differential expression.

Fig 1. Differential expression of circRNAs between IH and adjacent skin tissues by microarray. (A) Box plot showed that all the 8 samples were normalized. (B) Scatter-Plot was used for assessing the variation of circRNA expression between IH and adjacent skin tissues. The circRNAs above the top and below the bottom green lines indicated > 2.0-fold change in circRNAs between the two groups. (C) Volcano Plots were displayed for visualizing the differential expression of circRNAs. The red points in the plot represent the differentially expressed circRNAs with statistical significance. (D) Hierarchical cluster analysis of all the deregulated circRNAs.

https://doi.org/10.1371/journal.pone.0187581.g001
qRT-PCR validation

Total RNAs of 10 paired IH and adjacent skin tissues were reverse transcribed to synthesize cDNA by Gene Amp PCR System 9700 (Applied Biosystems, Carlsbad, USA). The selected circRNAs should meet the criteria that fold change was more than 4 and raw intensity of each sample was greater than 100. In addition, circRNAs with miRNA response elements (MREs) related to tumor progression and angiogenesis reported in the literatures were selected preferentially. Finally, 8 circRNAs were selected, including 5 up-regulated circRNAs (circRNA_100709, circRNA_102116, circRNA_051239, circRNA_100933 and circRNA_102039) and three down-regulated circRNAs (circRNA_023016, circRNA_001654 and circRNA_104310), for amplification by specific divergent primers (S1 Table). The housekeeping gene Human β-actin was selected as an internal reference. All cDNAs were assembled in the ViiA 7 real-time PCR System (Applied Biosystems) in triplicates each. The reaction was based on the following procedures: 95˚C, 10 min; 40 PCR cycles (95˚C, 10 s; 60˚C, 1 min). The single-peak appearance of the melt curve demonstrated the specificity of PCR primers. The relative level of circRNAs was computed by the $2^{-\Delta\Delta Ct}$ method.

Construction of circRNA-miRNA-mRNA networks

The miRNA response elements (MREs) of circRNAs was predicted using Arraystar’s miRNA target prediction software based on TargetScan [29] and miRanda [30]. The interaction of circRNAs

| Table 2. Top 25 up-regulated circRNAs in IH. |
|---------------------------------------------|
| circRNA       | P-value | FDR  | FC     | chrom | strand | type  | Gene Symbol |
|----------------|---------|------|--------|-------|--------|-------|-------------|
| hsa_circRNA_100709 | 0.012   | 0.131| 140.473| chr10 | -      | exonic | FAM53B     |
| hsa_circRNA_102116 | 0.025   | 0.168| 39.712 | chr17 | -      | exonic | ZNF652     |
| hsa_circRNA_051239 | 0.024   | 0.166| 30.206 | chr19 | -      | exonic | ATP5SL     |
| hsa_circRNA_051238 | 0.029   | 0.179| 11.627 | chr19 | -      | exonic | ATP5SL     |
| hsa_circRNA_101214 | 0.022   | 0.161| 8.862  | chr12 | +      | exonic | GPR133     |
| hsa_circRNA_109933 | 0.001   | 0.070| 7.844  | chr11 | -      | exonic | NOX4       |
| hsa_circRNA_102538 | 0.031   | 0.182| 6.174  | chr19 | +      | exonic | CAPNS1     |
| hsa_circRNA_401782 | 0.015   | 0.143| 5.473  | chr17 | +      | exonic | TAF15      |
| hsa_circRNA_101439 | 0.004   | 0.093| 5.430  | chr14 | -      | exonic | WARS       |
| hsa_circRNA_101985 | 0.045   | 0.209| 5.426  | chr17 | +      | exonic | MAP2K4     |
| hsa_circRNA_100945 | 0.005   | 0.107| 5.218  | chr11 | -      | exonic | GUCY1A2    |
| hsa_circRNA_104162 | 0.003   | 0.088| 5.128  | chr6  | -      | exonic | HACE1      |
| hsa_circRNA_403382 | 0.010   | 0.126| 4.192  | chr5  | +      | exonic | RASGRF2    |
| hsa_circRNA_102039 | 0.004   | 0.097| 4.814  | chr17 | +      | exonic | TAF15      |
| hsa_circRNA_023983 | 0.020   | 0.156| 4.728  | chr11 | -      | exonic | NOX4       |
| hsa_circRNA_000300 | 0.001   | 0.073| 4.640  | chr10 | +      | exonic | PRKG1       |
| hsa_circRNA_402294 | 0.000   | 0.048| 4.265  | chr2  | +      | exonic | ACTR2       |
| hsa_circRNA_001992 | 0.004   | 0.098| 4.190  | chrX  | -      | exonic | FIRRE       |
| hsa_circRNA_104163 | 0.008   | 0.118| 3.929  | chr6  | -      | exonic | HACE1       |
| hsa_circRNA_016121 | 0.009   | 0.121| 3.822  | chr1  | +      | exonic | SOX13       |
| hsa_circRNA_007104 | 0.008   | 0.109| 3.772  | chr12 | -      | exonic | DPY19L2     |
| hsa_circRNA_101996 | 0.001   | 0.068| 3.674  | chr17 | +      | exonic | SPECC1      |
| hsa_circRNA_103837 | 0.016   | 0.145| 3.647  | chr5  | +      | exonic | ITGA1       |
| hsa_circRNA_102881 | 0.011   | 0.127| 3.629  | chr2  | -      | exonic | HECW2       |
| hsa_circRNA_404446 | 0.008   | 0.106| 3.589  | chr1  | -      | exonic | CAPZB       |

FDR: False discovery rate, FC: Fold change

https://doi.org/10.1371/journal.pone.0187581.t002
and miRNAs were displayed by Cytoscape 3.01. The target genes of circRNAs were obtained by the integration of miRWalk 2.0 (miRWalk, miRanda, PITA, Targetscan) [31] and mRNA profile (GSE78811) previously [13]. GO analysis was used to predict the potential functions of the target genes by the Database for Annotation, Visualization, and Integrated Discovery (DAVID) online tool [32,33], including the categories of biological process (BP), molecular function (MF) and cellular component (CC). KEGG Ontology-Based Annotation System (KOBAS) 2.0 was used to proceed the pathway analysis of target genes, which incorporates five pathway databases [KEGG Pathway, PID, BioCyc, Reactome, and Panther] [34].

Statistical analysis

All data were presented as the mean ± standard error of mean (SEM). Student’s t-test (two-tailed) was used for data analysis. GraphPad Prism 5 and Microsoft Office were utilized for other statistics. P < 0.05 was considered to be statistically significant.

Results

Analysis of differentially expressed circRNAs

In total, 13617 circRNAs were analyzed by microarray in 4 pairs of IH and adjacent skin tissues (S2 Table). Box plot demonstrated the intensity of all the samples after normalization (Fig 1A).

| circRNA                | P-value | FDR  | FC   | chrom | strand | type    | Gene Symbol |
|------------------------|---------|------|------|-------|--------|---------|-------------|
| hsa_circRNA_000881     | 0.002   | 0.087| 23.090| chr10 | +      | intronic | MSI2        |
| hsa_circRNA_023016     | 0.002   | 0.079| 16.953| chr17 | +      | exonic   | RBM4        |
| hsa_circRNA_001654     | 0.005   | 0.102| 14.761| chr11 | +      | intronic | CNPY3       |
| hsa_circRNA_405814     | 0.000   | 0.056| 14.024| chr6  | +      | intronic | ZNF470      |
| hsa_circRNA_101491     | 0.009   | 0.121| 13.924| chr19 | +      | exonic   | MAPKBP1     |
| hsa_circRNA_406655     | 0.002   | 0.088| 10.866| chr15 | -      | intronic | CTC-228N24.3|
| hsa_circRNA_406698     | 0.002   | 0.087| 10.626| chr5  | +      | intergenic| *           |
| hsa_circRNA_001490     | 0.017   | 0.148| 10.318| chr5  | +      | exonic   | KIF2A       |
| hsa_circRNA_001409     | 0.007   | 0.115| 10.247| chr5  | +      | intronic | DGR8        |
| hsa_circRNA_001653     | 0.004   | 0.098| 9.935  | chr22 | +      | intronic | DUSP22      |
| hsa_circRNA_104310     | 0.029   | 0.178| 9.730  | chr6  | +      | exonic   | ZDHHC4      |
| hsa_circRNA_103801     | 0.015   | 0.142| 9.427  | chr7  | -      | exonic   | MYO10       |
| hsa_circRNA_406157     | 0.035   | 0.189| 8.828  | chr5  | +      | intragenic| APAT3       |
| hsa_circRNA_103372     | 0.028   | 0.177| 8.561  | chr21 | -      | exonic   | IP6K2       |
| hsa_circRNA_002086     | 0.002   | 0.083| 8.450  | chr3  | -      | exonic   | LOC401320   |
| hsa_circRNA_081481     | 0.044   | 0.209| 8.296  | chr7  | +      | exonic   | FBXO24      |
| hsa_circRNA_406768     | 0.033   | 0.185| 8.274  | chr7  | -      | exonic   | MDGA1       |
| hsa_circRNA_025522     | 0.032   | 0.183| 7.817  | chr6  | -      | exonic   | ARHGDI      |
| hsa_circRNA_102445     | 0.021   | 0.158| 7.562  | chr19 | +      | exonic   | CARM1       |
| hsa_circRNA_405963     | 0.048   | 0.216| 7.417  | chr2  | +      | intronic | UGGT1       |
| hsa_circRNA_001459     | 0.012   | 0.134| 7.281  | chr11 | -      | intronic | SPI1        |
| hsa_circRNA_092418     | 0.028   | 0.177| 6.929  | chr15 | +      | intronic | B2M         |
| hsa_circRNA_101522     | 0.027   | 0.175| 6.874  | chr15 | -      | exonic   | DMXL2       |
| hsa_circRNA_103361     | 0.038   | 0.194| 6.434  | chr3  | -      | exonic   | SMARCC1      |
| hsa_circRNA_103269     | 0.034   | 0.187| 6.387  | chr22 | -      | exonic   | LMF2         |

FDR: False discovery rate, FC: Fold change
*circRNA located outside of the known gene locus

https://doi.org/10.1371/journal.pone.0187581.t003
Differentially expressed circRNAs between IH and adjacent skin tissues were acquired based on fold change filtering (Fig 1B). Finally, 234 up- and 374 down-regulated circRNAs (S3 Table) were identified by fold change ≥ 2.0 and P-value < 0.05 (Fig 1C). Hierarchical clustering was performed to visualize the differential circRNAs (Fig 1D). The top 25 up- and down-regulated circRNAs were displayed in Tables 2 and 3. The classification schematic revealed that up-regulated circRNAs included 211 exonic, 12 intronic, and 11 intragenic, while the down-regulated circRNAs included 256 exonic, 65 intronic, 36 intragenic, 8 intergenic, and 9 antisense (Fig 2A). In addition, we summarized the localization of circRNAs on human chromosomes (Fig 2B). The data showed that the expression of circRNA in IH is much different from that of adjacent skin tissues.

qRT-PCR verification of selected circRNAs

On the basis of microarray raw intensity and downstream microRNAs, we selected 8 circRNAs from the most significant circRNAs for further verification. The expression of selected circRNAs was substantiated by qRT-PCR in 10 pairs of IH and adjacent skin tissues including the previous microarray group. As a result, six of them (circRNA_100709, circRNA_102116, circRNA_051239, circRNA_100933, circRNA_102039, and circRNA_104310) had the same change direction with microarray results (Fig 3). The other two circRNAs (circRNA_023016 and circRNA_001654) showed a similar expression level between IH and skin tissues. Finally, two up-regulated circRNAs (circRNA_100933 and circRNA_100709) and one down-regulated circRNA (circRNA_104310) were validated with statistical significance.
Construction of circRNA-miRNA-mRNA network

According to PCR results, the most significant up- (circRNA_100933, p < 0.001) and down-regulated circRNA (circRNA_104310, p < 0.05) were selected for further study. In order to explore the functions of circRNAs, we constructed the circRNA-miRNA-mRNA networks based on bioinformatics and the mRNA profile (GSE78811) published by our group previously. Firstly, MREs of circRNAs were predicted by Arraystar’s miRNA target prediction software. In total, 3019 MREs of circRNAs were detected (S3 Table). The interaction between circRNAs and their MREs were represented by Cytoscape (S1 Fig). The potential MREs of hsa_circRNA_100933 were miR-1298-3p, miR-892b, miR-2113, and miR-137, miR-514a-5p (Fig 4A). Moreover, the potential MREs of hsa_circRNA_104310 included miR-499a-3p, miR-1271-3p, miR-216a-3p, miR-197-3p, and miR-489-3p (Fig 4B). Then, 100 and 94 target genes of hsa_circRNA_100933 and hsa_circRNA_104310 were acquired by integration of the target gene prediction and mRNA profile (GSE78811), respectively. The hsa_circRNA_100933/hsa_circRNA_104310-miRNA-mRNA networks were illustrated using Cytoscape (Fig 5).

GO and pathway analysis of target genes

To gain further insight into the function of target genes, GO and pathway analysis was conducted using DAVID and KOBAS. The top five significant GO terms of each subgroup (BP, CC, MF) were displayed. Intriguingly, the hsa_circRNA_100933-targeted genes were primarily involved in the physiological processes including epithelial cell migration, epithelium migration, vasculature development, and tissue migration (Fig 6A). The top ten pathway terms were
also displayed (Fig 6B), which encompassed several angiogenesis-related pathways, such as signaling by EGFR; EGFR interacts with phospholipase C-gamma and Rap1 signaling pathway. In addition, the significant GO terms of hsa_circRNA_104310 included growth,
developmental growth, cellular lipid metabolic processes, and intracellular signal transduction (Fig 7A). Moreover, the HIF signaling pathway was among the top ten pathways of hsa_circRNA_104310 (Fig 7B) that played a vital role in the pathogenesis of IH.

**Discussion**

The present study, for the first time, examined the expression of circRNAs in IH and identified 234 up- and 374 down-regulated circRNAs. A majority of the deregulated circRNAs were exonic; the intronic type was more regular in down-regulated circRNAs than those who are up-regulated. In addition, the expression of hsa_circRNA_100933, hsa_circRNA_100709 and hsa_circRNA_104310 was confirmed by PCR. CircRNAs are a large group of stable ncRNAs, which are widely found in various cells and exhibit a critical regulatory role in gene expression.
In 2013, Memczak et al. [36] successfully identified more than 1980 kinds of circRNAs using high-throughput technology. Since then, the function of circRNAs in the tumor formation was gradually recognized. The characteristics of circRNAs include high stability, wide variety, transcription from exons, rich MREs, sequence specificity, and conserved across species [37]. These features indicate that circRNAs play a critical role in both transcriptional and post-transcriptional levels, and may serve as a new diagnostic and therapeutic target of IH.

The functional study of circRNAs, which designates them to act as miRNA sponges, is an emerging research area of physiological processes and tumor formation. The common circRNA, CDR1as/ciRS-7, which harbors 71 miR-7 binding sites [38], was shown as the inhibitor of miR-7 in embryonic zebrafish midbrain [36] and islet cells [39,40]. The present study predicted the interaction of circRNAs and miRNAs. Among them, miR-137 targeted by circRNA_100933, has been reported to act as tumor suppressor in various tumors [41,42]. Previous study demonstrated that miR-216a-3p, one of the target miRNAs of circRNA_104310, inhibited gastric and colorectal cancer cell proliferation and migration [43,44]. Moreover, hsa-520d-3p and hsa-miR-520a-5p targeted by hsa_circRNA_001654 and hsa_miR-518f-3p targeted by hsa_circRNA_102116 were implicated as biomarkers in IH [14], suggesting the potency of circRNAs as biomarker candidates in IH.

As circRNA and mRNA can compete for the same miRNA binding sites according to circRNA theory [45], we constructed two circRNA-miRNA-mRNA networks with an integration of miRWalk prediction and mRNA profile(GSE78811) to gain further insight into the function of circRNAs in IH. As a result, 100 target genes of hsa_circRNA_100933 and 94 target genes of hsa_circRNA_104310 were acquired. Moreover, GO and pathway analysis suggested a number of angiogenesis and vascular development-related physiological processes and pathways. The hsa_circRNA_100933-targeted genes were primarily involved in

![Fig 6. GO (A) and pathway analysis (B) of hsa_circRNA_100933 targeted genes.](https://doi.org/10.1371/journal.pone.0187581.g006)
neovascularization-related biological processes including epithelial cell migration, epithelium migration, vasculature development, and tissue migration. EGFR signaling and Rap1 signaling pathways that included the top 10 pathway terms, played a major role in vasculogenesis and angiogenesis of several vascular diseases [46,47]. Among the top 10 pathways of hsa_circRNA_104310-targeted genes, HIF-1 signaling pathway has been demonstrated as an essential pathogenic mechanism in IH, which could regulate angiogenesis via VEGF signaling [48]. The bioinformatics data indicated that circRNAs may be involved in molecular mechanisms underlying neovascularization and may play a vital role in the mechanism of IH. Nevertheless, the function of circRNAs and the circRNA-miRNA-mRNA network in IH requires further investigations.

**Conclusion**

This is the first study to profile circRNAs expression in IH. Furthermore, the circRNA/miRNA interaction was predicted, and circRNA-miRNA-mRNA networks were constructed using bioinformatics tools. The GO and pathway analysis identified many vasculogenesis- and
angiogenesis-related pathways, which may provide new insights into the pathogenesis of IH. However, the function of circRNAs in IH requires further in vitro and in vivo studies.

Supporting information

S1 Table. qRT-PCR primers of circRNAs.
(DOCX)

S2 Table. CircRNA expression profiling data.
(XLS)

S3 Table. Differentially-expressed circRNAs.
(XLS)

S1 Fig. Interaction between circRNAs and miRNAs. (A). Deregulated circRNAs and their MREs, including 234 up regulated circRNAs (red nodes), 374 down deregulated circRNAs (yellow nodes) and MREs (blue nodes). (B). The most significant differentially expressed circRNAs and MREs were enlarged.
(TIF)

Acknowledgments

Microarray experiments were performed by KangChen Biotech (Shanghai, China).

Author Contributions

Conceptualization: Cong Fu, Ran Huo.
Data curation: Cong Fu, Ran Huo.
Formal analysis: Cong Fu, Ran Huo.
Funding acquisition: Ran Huo.
Investigation: Cong Fu, Renrong Lv, Guangqi Xu, Linfeng Zhang, Jianhai Bi.
Methodology: Cong Fu, Ran Huo.
Project administration: Ran Huo.
Resources: Cong Fu, Renrong Lv, Li Lin, Xiaowen Liu.
Software: Cong Fu.
Supervision: Ran Huo.
Validation: Cong Fu, Renrong Lv, Guangqi Xu.
Visualization: Cong Fu, Linfeng Zhang, Ran Huo.
Writing – original draft: Cong Fu.
Writing – review & editing: Guangqi Xu, Ran Huo.

References

1. Anderson KR, Schoch JJ, Lohse CM, Hand JL, Davis DM, et al. (2016) Increasing incidence of infantile hemangiomas (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. Journal of the American Academy of Dermatology 74: 120–126. https://doi.org/10.1016/j.jaad.2015.08.024 PMID: 26494585
2. Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, et al. (2014) Prospective study of infantile haemangomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol 170: 907–913. https://doi.org/10.1111/bjd.12804 PMID: 24641194

3. Haggestrom AN, Drolet BA, Basela E, Chamlin SL, Garzon MC, et al. (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150: 291–294. https://doi.org/10.1016/j.jspediatr.2006.12.003 PMID: 17307549

4. Itinteang T, Withers AH, Davis PF, Tan ST (2014) Biology of infantile hemangioma. Front Surg 1: 38. https://doi.org/10.3389/fsurg.2014.00038 PMID: 25593962

5. Ji Y, Chen S, Li K, Li L, Xu C, et al. (2014) Signaling pathways in the development of infantile hemangioma. J Hematol Oncol 7: 13. https://doi.org/10.1186/1756-8722-7-13 PMID: 24479731

6. Leaute-Labrèze C, Sans-Martin V (2010) [Infantile hemangioma]. Presse Med 39: 499–510. https://doi.org/10.1016/j.lpm.2009.10.015 PMID: 20207100

7. Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J (2004) Endothelial progenitor cells in infantile hemangioma. Blood 103: 1373–1375. https://doi.org/10.1182/blood-2003-08-2859 PMID: 14576053

8. Sun ZY, Yi CG, Zhao H, Yin GQ, Gao M, et al. (2008) Infantile hemangioma is originated from placental trophoblast, fact or fiction? Med Hypotheses 71: 444–448. https://doi.org/10.1016/j.mehy.2008.03.013 PMID: 18440158

9. North PE, Waner M, Mizeracki A, Mihm MC Jr. (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31: 11–22. PMID: 10665907

10. Przewrati l P, Sitkiewicz A, Andrzejewska E (2010) Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine 49: 141–147. https://doi.org/10.1016/j.cyto.2009.11.012 PMID: 20015661

11. Zou HX, Jia J, Zhang WF, Sun ZJ, Zhao YF (2013) Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma. Cardiovasc Pathol 22: 203–210. https://doi.org/10.1016/j.carpath.2012.10.001 PMID: 23151525

12. Esteller M (2011) Non-codin g RNAs in human disease. Nat Rev Genet 12: 861–874. https://doi.org/10.1038/nrg3074 PMID: 22094949

13. Liu X, Lv R, Zhang L, Xu G, Bi J, et al. (2016) Long noncoding RNA expression profile of infantile hemangiom a identified by microarray analysis. Tumour Biol.

14. Strub GM, Kirsh AL, Whipple ME, Kuo WP, Keller RB, et al. (2016) Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma. JCI Insight 1: e88856. https://doi.org/10.1172/jci.insight.88856 PMID: 27686822

15. Li D, Li P, Guo Z, Wang H, Pan W (2017) Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway. Int J Mol Med 39: 757–763. https://doi.org/10.3892/ijmm.2017.2863 PMID: 28112362

16. Gao F, Wang FG, Liu RR, Xue F, Zhang J, et al. (2017) Epigenetic silencing of miR-130a ameliorates hemangioma by targeting tissue factor pathway inhibitor 2 through FAK/PI3K/Rac1/mdm2 signaling. Int J Oncol 50: 1821–1831. https://doi.org/10.3892/ijo.2017.3943 PMID: 28393235

17. Zheng Q, Bao C, Guo W, Li S, Chen J, et al. (2016) Circular RNA profiling reveals an abundant cir-chIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun 7: 11215. https://doi.org/10.1038/ncomms1215 PMID: 27050392

18. Cocquerelle C, Mascr ez B, Heteu d, Bailleul B (1993) Mis-splicing yields circular RNA molecules. Faseb j 7: 155–160. PMID: 7678559

19. Negro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, et al. (1991) Scrambled exons. Cell 64: 607–613. PMID: 1991322

20. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO (2012) Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One 7: e30733. https://doi.org/10.1371/journal.pone.0030733 PMID: 22319583

21. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, et al. (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495: 384–388. https://doi.org/10.1038/nature11993 PMID: 23446346

22. Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO (2013) Cell-type specific features of circular RNA expression. PLoS Genet 9: e1003777. https://doi.org/10.1371/journal.pgen.1003777 PMID: 24039610

23. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146: 353–358. https://doi.org/10.1016/j.cell.2011.07.014 PMID: 21802130

24. Chen I, Chen CY, Chuang TJ (2015) Biogenesis, identification, and function of exonic circular RNAs. Wiley Interdiscip Rev RNA 6: 563–579. https://doi.org/10.1002/wrna.1294 PMID: 26230526
25. Sand M, Bechara FG, Gambichler T, Sand D, Bromba M, et al. (2016) Circular RNA expression in cutaneous squamous cell carcinoma. Journal of Dermatological Science 83: 210–218. https://doi.org/10.1016/j.jdermsci.2016.05.012 PMID: 27298156

26. Ahmed I, Karedath T, Andrews SS, Al-Azwani IK, Ali Mohamoud Y, et al. (2016) Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget.

27. Sand M, Bechara FG, Sand D, Gambichler T, Hahn SA, et al. (2016) Circular RNA expression in basal cell carcinoma. Epigenomics 8: 619–632. https://doi.org/10.2217/epi-2015-0019 PMID: 27097056

28. Boeckel JN, Jae N, Heumuller AW, Chen W, Boon RA, et al. (2015) Identification and Characterization of Hypoxia-Regulated Endothelial Circular RNA. Circ Res 117: 884–890. https://doi.org/10.1161/CIRCRESAHA.115.306319 PMID: 26377962

29. Enright AJ, John B, Gaul U, Tuschl T, Sander C, et al. (2003) MicroRNA targets in Drosophila. Genome Biol 5: R1. https://doi.org/10.1186/gb-2003-5-1-r1 PMID: 14709173

30. Pasquinelli AE (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 13: 271–282. https://doi.org/10.1038/nrg3162 PMID: 22411466

31. Dweep H, Stich C, Pandey P, Gretz N (2011) miRWa lk—database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 44: 839–847. https://doi.org/10.1016/j.jbi.2011.05.002 PMID: 21605702

32. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57. https://doi.org/10.1038/nprot.2008.211 PMID: 19131956

33. Tweedie S, Ashburner M, Falls K, Leyland P, McQuilton P, et al. (2009) FlyBase: enhancing Drosophila Gene Ontology annotations. Nucleic Acids Res 37: D555–559. https://doi.org/10.1093/nar/gkn788 PMID: 18948289

34. Xie C, Mao X, Huang J, Ding Y, Wu J, et al. (2011) KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 39: W316–322. https://doi.org/10.1093/nar/gkr483 PMID: 21715396

35. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, et al. (2013) Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19: 141–157. https://doi.org/10.1261/rna.035667.112 PMID: 23249747

36. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, et al. (2013) Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495: 333–338. https://doi.org/10.1038/nature11928 PMID: 23446348

37. Cortes-Lopez M, Miura P (2016) Emerging Functions of Circular RNAs. Yale J Biol Med 89: 527–537. PMID: 28018143

38. Guo JU, Agarwal V, Guo H, Bartel DP (2014) Expanded identification and characterization of mammalian circular RNAs. Genome Biol 15: 409. https://doi.org/10.1186/s13059-014-0409-z PMID: 25070500

39. Xu H, Guo S, Li W, Yu P (2015) The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. Sci Rep 5: 12453. https://doi.org/10.1038/srep12453 PMID: 26211738

40. Hansen TB, Kjems J, Damgaard CK (2013) Circular RNA and miR-7 in cancer. Cancer Res 73: 5609–5612. https://doi.org/10.1158/0008-5472.CAN-13-1568 PMID: 24014594

41. Huang J, Song J, Qu M, Wang Y, An Q, et al. (2017) MicroRNA-137 and microRNA-195* inhibit vasculogenesis in brain arteriovenous malformations. Ann Neurol.

42. Peres J, Kwesi-Malipenda EM, Rambow F, Larue L, Prince S (2017) The tumour suppressor, miR-137, inhibits malignant melanoma migration by targeting the TBX3 transcription factor. Cancer Lett 405: 111–119. https://doi.org/10.1016/j.canlet.2017.07.018 PMID: 28757416

43. Wang D, Li Y, Zhang C, Li X, Yu J (2017) MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5. J Cell Biochem.

44. Wu Y, Zhang J, Zheng Y, Ma C, Liu XE, et al. (2017) MiR-216a-3p Inhibits the Proliferation, Migration, and Invasion of Human Gastric Cancer Cells via Targeting RUNX1 and Activating the NF-kappaB Signaling Pathway. Oncol Res.

45. Chen Y, Li C, Tan C, Liu X (2016) Circular RNAs: a new frontier in the study of human diseases. J Med Genet 53: 359–365. https://doi.org/10.1136/jmedgenet-2016-103758 PMID: 26945092

46. Chen GJ, Karajannis MA, Newcomb EW, Zagazig D (2010) Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. J Neurooncol 99: 195–200. https://doi.org/10.1007/s11060-010-0125-9 PMID: 20730556

47. Yu X, Li W, Deng Q, You S, Liu H, et al. (2016) Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production. Mol Carcinog.
48. Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, et al. (2012) Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Ann Surg 256: 146–156. https://doi.org/10.1097/SLA.0b013e318254ce7a PMID: 22580939